Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Summary

This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2021-12-22

Primary completion

2024-09-30

Completion

2026-03-31

Drugs

Indications